Navigation Links
Thoratec Reports 44 Percent Increase in Third Quarter Revenues
Date:10/30/2008

) for bridge-to-transplantation, which helped generate a 68 percent increase in revenues from our Cardiovascular Division versus a year ago," said Gary F. Burbach, president and chief executive officer of Thoratec. "In addition to experiencing greater implant activity, we also added 17 new HeartMate II centers during the quarter. We have now added a total of 43 new centers, surpassing our goal of adding 40 new centers during the year," he added.

"I am very pleased with our results to date and based on our performance through the first three quarters of the year, we believe we are positioned to have a highly successful 2008. At the same time, we are implementing programs to add new HeartMate II centers and increase activity from referring cardiologists that are designed to lay a foundation for long-term growth," Burbach added.

The company also updated enrollment in the Destination Therapy (DT) arm of its pivotal clinical trial for the HeartMate II. As of October 24, 2008, there were 607 patients enrolled in the DT arm of the trial, including 366 patients in the randomized portion of the study.

FINANCIAL HIGHLIGHTS

Thoratec reported revenues of $80.8 million in the third quarter of 2008 compared with revenues of $56.1 million in the third quarter of 2007. Cardiovascular Division revenues were $57.1 million versus $34.0 million in the same period a year ago. Revenues at ITC were $23.7 million versus $22.0 million a year ago.

GAAP gross margin in the third quarter of 2008 was 60.3 percent versus 57.7 percent a year ago. Non-GAAP gross margin, which excludes SFAS No. 123R expense and is described later in this press release, was 60.8 percent versus 58.5 percent a year ago. The improvement in gross margin reflects primarily the increase in average selling prices associated with U.S. commercial approval of the HeartMate II. This was partially offset by lower margins at ITC primarily related to geographic and product mix, and unfavorable m
'/>"/>

SOURCE Thoratec Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Thoratec Schedules Third Quarter 2008 Conference Call, Webcast
2. Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History
3. Thoratec Presentation at JP Morgan Conference to be Webcast
4. Thoratec Announces Appointment of Steven H. Collis to Board of Directors
5. Thoratec Presentation at Bear Stearns Conference To Be Webcast
6. Thoratec Announces HeartMate II(R) PMA Will be Reviewed by FDA Advisory Panel
7. Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
8. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
9. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
10. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
11. United Therapeutics Reports Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... D.C., September 30, 2014 Applying a well-known ... researchers at Harvard University has demonstrated the ability ... -- work that holds promise for making future, ... detailing the sides of next-gen rocket ships and ... light passes through oil in water, it becomes ...
(Date:9/30/2014)... , Sept. 30, 2014 Report ... segments with highest potential revenues Do you want ... report gives you revenue predictions for those biological ... those therapies you find financial data, R&D trends, ... you get sales forecasts to 2024 at overall ...
(Date:9/30/2014)... Proove Biosciences , the commercial and research ... new genetic test built upon research from their published ... will provide physicians with an objective way to understand ... stratified between individuals. With this new test, physicians will ... genetic predisposition that will affect their pain tolerance. , ...
(Date:9/30/2014)... , September 30, 2014 ... browsing of chemistry in documents ... solutions and consulting services for life science research, ... and generate Markush structures from documents. ... intellectual property, however generating and understanding Markush structures ...
Breaking Biology Technology:Taking thin films to the extreme 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2
... Inc. (Nasdaq: INSM ), a developer of follow-on ... 23, 2009, NASDAQ issued a notice further extending the suspension ... and those rules requiring a minimum market value of publicly ... through Friday, July 17, 2009, and the original rules will ...
... CALGARY, March 25 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ... the completion of patient enrolment in its U.K. ... intravenous administration of REOLYSIN(R) in combination with gemcitabine ... and head and neck. The principal investigators are ...
... 25 Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: ... of Shareholders held on Tuesday, March 24, 2009.At the ... of shares of authorized stock (including an increase in ... proposal to increase the number of shares available for ...
Cached Biology Technology:Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule 2Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial 2Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial 3Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders 2
(Date:9/30/2014)... scientists and engineers, led by Clemson University associate ... million grant from the U.S. Department of Energy,s ... a direct positive impact on South Carolina in ... radioactive contaminants. , "Understanding the scientific and engineering ... aspects of nuclear technologies is imperative if South ...
(Date:9/30/2014)... England Journal of Medicine reports positive results of ... against the subset of lung cancer marked by rearrangement ... 50 patients with advanced non-small cell lung cancer testing ... 72 percent, with 3 complete responses and 33 partial ... for the disease to resume its growth after being ...
(Date:9/30/2014)... in German . ... expensive foods in the world. Because they grow underground, people ... distinctive smell of truffles is not only of interest to ... direction of the Goethe University Frankfurt have discovered that the ... which are trapped inside truffle fruiting bodies. , White truffles ...
Breaking Biology News(10 mins):Researchers get $5.25 million to advance nuclear technologies in South Carolina 2NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer 2On the trail of the truffle flavor 2
... the heels of his discovery in Montana of the first ... Martin has found evidence of more dinosaur burrows this ... Australia. The find, to be published this month in ... dinosaurs of different species, in different hemispheres, and spanned millions ...
... BIRMINGHAM, Ala. The American Heart Association has pledged ... at Birmingham (UAB) biomedical engineering undergraduate students who are ... using hand-held remote controls from the Nintendo Wii video ... Islam and Zach Clark began work on the project ...
... available in German . , Infections ... often caused by bacteria called Pseudomonas aeruginosa. Once they ... virulence factors and can enter into a slimy state, ... of quorum sensing, which cells use to "sense" cell ...
Cached Biology News:Down Under dinosaur burrow discovery provides climate change clues 2Down Under dinosaur burrow discovery provides climate change clues 3UAB students' Nintendo Wii CPR earns American Heart Association support 2A matter of density, not quantity 2
DryStrip aligners, 4. Category: Electrophoresis Systems & Standards & Reagents, IEF & SDS-PAGE & 2-D Electrophoresis, Multiphor II Kits & Components and Accessories....
...
... deuterium atoms at the 3, 3', 4, ... use as an internal standard for the ... spectrometry. PGE1 is the theoretical cyclooxygenase metabolite ... virtually undetectable in the plasma of normal ...
Assay Diluent Trial Pack, 4 x 100 mL...
Biology Products: